Skip to content
  • Home
  • About
  • News
    • Top
    • Recent News
    • Archive
  • Account
    • Profile
    • Manage Corporate Account
    • Orders
    • Billing
    • Cancel
  • Subscription Plans
  • Contact
  • Login
  • Home
  • About
  • News
    • Top
    • Recent News
    • Archive
  • Account
    • Profile
    • Manage Corporate Account
    • Orders
    • Billing
    • Cancel
  • Subscription Plans
  • Contact
  • Login

Adcock Ingram Delisting After Natco Acquisition

Adcock Ingram delisting from the JSE is confirmed for November 11. Learn about the impact of the Natco Pharma acquisition.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Adcock Ingram Takeover Gets Green Light from Shareholders

Shareholders have approved the Adcock Ingram takeover by Natco Pharma, marking a new chapter for the pharmaceutical company.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Adcock Ingram Reports Flat Profit Despite Winter Surge

Adcock Ingram reports steady annual profits as winter demand for Panado and Corenza-C drives growth in the second half.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Bidvest’s Role in Adcock Ingram Takeover Bid

Learn how Bidvest's partnership with Natco Pharma impacts Adcock Ingram and shareholder rights amid a new takeover bid.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Adcock Ingram to Delist Amidst Corporate Changes

Adcock Ingram is set to delist from the JSE as Natco Pharma partners with Bidvest in a major take-private deal.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here